Upcoming Allied Market Research
Antidiabetic Drug Market

Antidiabetic Drug Market

by Drug Type (Insulin, DPP-4 inhibitord, GLP-1 Receptor Agonists, SGLT2 Inhibitors, Others), by Diabetes Type (Type 1, Type2) by Route of Administration (Oral, Subcutaneous, Intravenous) by Distribution Channel (Online , Offline , Retail Pharmacies) : Global Opportunity Analysis and Industry Forecast, 2022-2032

Report Code: A47491
Pages: NA
May 2023 | 51 Views
Author(s) : Vineet K
Tables: NA
Charts: NA
  • Formats*:

  • pdf

    Single User License, Five User
    License & Enterprise User License

  • xls

    Data Pack Excel License

  • ppt

    It comes with the additional cost
    of $2500.00 contact sales.

Diabetes is a condition where there is a lack of insulin in the body and the presence of high blood glucose levels. Antidiabetic drugs are prescription medications used to treat diabetes. It lowers blood sugar levels by activating gluconeogenic enzymes and glycogen phosphorylase, which reveals slower rates of glycogenolysis and gluconeogenesis. The demand for antidiabetic drugs is anticipated to increase significantly owing to an increase in the prevalence of diabetes. For instance, as per the statistics by World Health Organization (WHO) more than 422 million people suffer from diabetes globally and around 1.5 million deaths are recorded each year. Also, the number of patients suffering from diabetes is increasing rapidly in recent years due to unhealthy lifestyle habits and a lack of physical activities.
Antidiabetic drugs come in many various forms, such as insulin, pramlintide (Amylin), GLP-1 receptor agonists (like Byetta and Victoza), and oral hypoglycemics (tablets). According to the European Society of Cardiology, the number of patients suffering from diabetes is expected to reach 628.6 million by 2045. These factors are driving the research activities related to antidiabetic drugs that could save the lives of millions of people. For instance, along with diet and exercise, the U.S. Food and Drug Administration has approved Mounjaro (tripeptide) injectables to help adults with type 2 diabetes to help them in regulating their blood sugar levels. In clinical investigations, Mounjaro was compared to other diabetic treatments and found to be more effective at lowering blood sugar. 
Furthermore, increased glucose tolerance with age is anticipated to increase demand for antidiabetic drugs among the elderly which is anticipated to drive the antidiabetic drug market share in the coming years. At present, some of the widely used antidiabetic medications include metformin, insulin/analogs, gliptins, SGLT-2i, sulfonylurea, glitazones, GLP-1a (2.8%) and glucosidase inhibitors. These drugs help in regulating the blood glucose levels thereby reducing the risk of hypoglycemia. These factors are anticipated to generate excellent opportunities in the antidiabetic drugs industry during the forecast period.
Among metabolic disorders, the demand for antidiabetic medications is increasing rapidly surpassing that of cardiac drugs. These statistics reflect that the number of the diabetic patient population is increasing significantly. Hence, there have been huge research & development activities in the field of antidiabetic drugs market paving the way for new medications. For instance, in February 2023, Akums Drugs and Pharmaceuticals Ltd., the leading pharmaceutical company in India, has received approval from Drug Controller-General of India (DCGI) for the launch of novel anti-diabetic drug named Lobeglitazone.
However, the high cost of antidiabetic drugs and potential side effects associated with these drugs is anticipated to restrain the market growth during the projection timeframe. For instance, the consumption of metformin drug is linked with nausea, diarrhea, and bloating, and can lead to B12 deficiency.
The adoption of cutting-edge technologies such as artificial intelligence (AI) and machine learning (ML) in the pharmaceutical industry for drug development is predicted to drive the antidiabetic drug market growth. For instance, Tandem Diabetes Care announced in February 2022 that the Food and Drug Administration has approved a smartphone app for scheduling insulin delivery for diabetes patients. According to a statement from the company, it is the first mobile software that can supply insulin for iOS and Android users. 
 New product launches to flourish the market
In January 2023, Novo Nordisk introduced oral Semaglutide in tablet form to treat diabetes in India. The company also offers modern analogs and human insulin for the management of diabetes. For patients in India, Novo Nordisk is developing a once-weekly insulin regimen. The leading pharmaceutical company is conducting trials with 217 patients across 27 sites in India.
Teplizumab, the flagship investigational medication candidate of Provention Bio, has been introduced by Sanofi U.S. in October 2022 to postpone the onset of clinical type 1 diabetes (T1D). The partnership enables Prevention to use Sanofi's expertise and financial resources to support the introduction of teplizumab. 
Segment Overview:
By Drug Type: This segment is divided into insulin, DPP-4 inhibitord, GLP-1 receptor, agonists, SGLT2 inhibitors, and others. Among these, insulin sub-segment accounted for the highest market share. This growth is majorly owing to the product's high usage rates and potent therapeutic effects. In addition, this segment is anticipated to grow at a rapid pace during the projection period due to the launch of new products and the potential commercialization of items presently under development. 
By Diabetes Type: This segment is classified into type 1 and type 2 sub-segments. Among these, the type 2 diabetes mellitus (T2DM) has accounted for a highest market share in 2021. According to the WHO, more than 95% of people suffer from type 2 diabetes. This type of diabetes is primarily brought on by increased body weight and inactivity.
By Route of Administration: This segment is classified into oral, subcutaneous, and intravenous. Among these, the oral sub-segment is anticipated to grow at a significant rate during the analysis timeframe. The oral antidiabetic drug has high clinical efficacy, low cost, high adherence rate, safety, general availability, and other factors. 
By Distribution Channel: This segment is classified into online, offline, and retail pharmacies. Among these, retail pharmacies accounted for a significant share in the coming years. This is majorly owing to the increased availability of open-angle glaucoma medications through retail pharmacies and the rise in the proportion of retail pharmacies in developed countries. Furthermore, retail pharmacies are gaining huge popularity owing to the ease of accessibility of medications at an affordable price.
By Region: The market is segmented into North America, Europe, Asia-Pacific, and LAMEA. Among these, North America accounted for a significant share of antidiabetic drug market. This growth is majorly owing to increased adoption of modern insulin products such as Onglyza, Januvia, and Nesina, which are long-lasting and show quick relief. Growing awareness regarding diabetes, an increase in FDA product approvals, and extensive research & development activities are driving the antidiabetic drug market growth in the North America region. 
Competitive Analysis
Competitive analysis and profiles of the major antidiabetic drug market players, include Novo Nordisk India Pvt., Ltd., Sanofi, Merck & Co., Inc., Rahway, NJ USA, and its affiliates., Lilly, AstraZeneca, Boehringer Ingelheim International GmbH, Novartis AG, Johnson & Johnson Services Inc., Bayer AG, and Takeda Pharmaceutical Company Limited, company analysis is provided in this report. These companies have adopted key strategies such as product launches and acquisitions to improve their portfolio and stay competitive.

Antidiabetic Drug Market Report Highlights

Aspects Details
By Drug Type
  • Insulin
  • DPP-4 inhibitord
  • GLP-1 Receptor Agonists
  • SGLT2 Inhibitors
  • Others
By Diabetes Type
  • Type 1
  • Type2
By Route of Administration
  • Oral
  • Subcutaneous
  • Intravenous
By Distribution Channel
  • Online 
  • Offline 
  • Retail Pharmacies
By Region
  • North America  (U.S., Canada, Mexico)
  • Europe  (France, Germany, Italy, Spain, UK, Russia, Rest of Europe)
  • Asia-Pacific  (China, Japan, India, South Korea, Australia, Thailand, Malaysia, Indonesia, Rest of Asia-Pacific)
  • LAMEA  (Brazil, South Africa, Saudi Arabia, UAE, Argentina, Rest of LAMEA)
Key Market Players Novo Nordisk India Pvt Ltd, Sanofi, Merk & Co Inc, Eli Lilly and Company, AstraZeneca plc, Boehringer Ingelheim International GmbH, Novatis AG, Johnson & Johnson Services Inc., Bayer AG, takeda pharmaceuticals

Loading Table Of Content...

With collective industry experience of about 200 years of its analysts and experts, Allied Market Research (AMR) encompasses most infallible research methodology for its market intelligence and industry analysis. We do not only engrave the deepest levels of markets but also sneak through its slimmest details for the purpose of our market estimates and forecasts. Our approach helps in building greater market consensus view for size, shape and industry trends within each industry segment. We carefully factor in industry trends and real developments for identifying key growth factors and future course of the market. Our research proceeds are the resultant of high quality data, expert views and analysis and high value independent opinions. Our research process is designed to deliver balanced view of the global markets and allow stakeholders to make informed decisions.

We offer our clients exhaustive research and analysis based on wide variety of factual inputs, which largely include interviews with industry participants, reliable statistics and regional intelligence. Our in-house industry experts play instrumental role in designing analytic tools and models, tailored to the requirements of particular industry segment. These analytical tools and models sanitize the data & statistics and enhance the accuracy of our recommendations and advice. With AMR’s calibrated research process and 360` degree data-evaluation methodology, our clients are assured of receiving:

  • Consistent, valuable, robust and actionable data & analysis that can easily be referenced for strategic business planning
  • Technologically sophisticated and reliable insights through well audited and veracious research methodology
  • Sovereign research proceeds that present a tangible depiction of marketplace

With a strong methodology we are, therefore, confident that our research and analysis are most reliable and guarantees sound business planning.

Secondary research
We refer a broad array of industry sources for our secondary, which typically include; however, not limited to: Company SEC filings, annual reports, company websites, broker & financial reports and investor presentations for competitive scenario and shape of the industry

  • Patent and regulatory databases for understanding of technical & legal developments
  • Scientific and technical writings for product information and related preemptions
  • Regional government and statistical databases for macro analysis
  • Authentic new articles, web-casts and other related releases for market evaluation
  • Internal and external proprietary databases, key market indicators and relevant press releases for market estimates and forecast

Primary research
Our primary research efforts include reaching out participants through mail, tele-conversations, referrals, professional networks and face-to-face interactions. We are also in professional corporate relations with various companies that allow us greater flexibility for reaching out industry participants and commentators for interviews and discussions, fulfilling following functions:

  • Validates and improves the data quality and strengthens research proceeds
  • Further develops analyst team’s market understanding and expertise
  • Supplies authentic information about market size, share, growth and forecasts

Our primary research interview and discussion panels are typically composed of most experienced industry members. These participants include; however, not limited to:

  • Chief executives and VPs of leading corporations specific to industry
  • Product and sales managers or country heads; channel partners and top level distributors; banking, investments and valuation experts Key opinion leaders (KOLs)

Analyst tools and models
AMR has developed set of analyst tools and data models to supplement and expedite the analysis process. Corresponding to markets, where there is significant lack of information and estimates, AMR’s team of experts and analyst develop specific analyst tools and industry models to translate qualitative and quantitative industry indicators into exact industry estimates. These models also allow analysts to examine the prospects and opportunities prevailing in the market to accurately forecast the course of the market.

Call or Email us

U.S.-Canada Toll-free: +1-800-792-5285
Int'l : +1-503-894-6022
Europe : +44-845-528-1300
Email : help@alliedmarketresearch.com

Looking for Customization?

 Customization Request

Have a Question?

 Speak with Analyst

Any Confusion?

 Inquire Before Buying

Have a glance of the Report

  Enquiry Now

Purchase Full Report of
Antidiabetic Drug Market

Start reading.
This Report and over 19,950+ more Reports, Available with Avenue Library. T&C*.

  • Online Only
  • $3,570
  • Online cloud access only
  • Restricted print, copy, paste & download
  • Read only
  • Free industry update
    (Within 180 days)
  • Free report update in next update cycle
  • Data Pack
  • $3,840
  • Restricted to one authorized user
  • One print only
  • Available in
  • Free industry update
    (Within 180 days)
  •   Free report update in next update cycle
  • Single User
  • $5,730
  • Restricted to one authorized user
  • One print only
  • Available in
  • Free industry update
    (Within 180 days)
  •   Free report update in next update cycle
  • Five Users
  • $6,450
  • Limited to five authorized users
  • Print upto five copies
  • Available in
  • Free industry update
    (Within 180 days)
  •   Free report update in next update cycle
  • Enterprise

  • $9,600
  • Unlimited
  • Available in Excel & PDF
  • Free industry update
    (Within 180 days)
  •   Free report update in next update cycle
  • Library

  • $999 $ 1,175
    Per User/ Per month/ Billed annually
  • Published Content
  • Company Profiles
  • Newly Added Content Access
  • 10 PDF
  • 5 Excel Data
    Pack Downloads
  • 250 Company Profiles PDF Downloads
  • Buy Now

*Taxes/Fees, if applicable will be added during checkout. All prices in USD


Why Allied Market Research?


Infallible Methodology

To ensure high-level data integrity, accurate analysis, and impeccable forecasts

Analyst Support

For complete satisfaction


On-demand customization of scope of the report to exactly meet your needs


Targeted market view to provide pertinent information and save time of readers

Get fresh content delivered

Get insights on topics that are crucial for your business. Stay abreast of your interest areas.

Get Industry Data Alerts

Why Allied Market Research?

Infallible Methodology

To ensure high-level data integrity, accurate analysis, and impeccable forecasts

Analyst Support

For complete satisfaction


On-demand customization of scope of the report to exactly meet your needs


Targeted market view to provide pertinent information and save time of readers